ZNTL ZENTALIS PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, ZENTALIS PHARMACEUTICALS INC reported revenue of n/a, net income of −$42.3M and diluted EPS of −$0.59; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.

ZNTL annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$153M, net income −$137M (margin n/a), EPS −$1.91
• Fiscal year ended Dec 2024: revenue $67.4M, gross profit n/a, operating income −$191M, net income −$166M (margin -246.0%), EPS −$2.33
• Fiscal year ended Dec 2023: revenue $0, gross profit n/a, operating income −$300M, net income −$292M (margin n/a), EPS −$4.47
• Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$227M, net income −$237M (margin n/a), EPS −$4.48
• Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$217M, net income −$159M (margin n/a), EPS −$3.72

ZNTL quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$42.3M, EPS −$0.59
• Quarter ended Mar 31, 2026: revenue n/a, net income −$35.4M, EPS −$0.50
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$35.2M, EPS −$0.50
• Quarter ended Sep 30, 2025: revenue $0, net income −$26.7M, EPS −$0.37
• Quarter ended Jun 30, 2025: revenue $0, net income −$26.9M, EPS −$0.37
• Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$48.3M, EPS −$0.67
• Quarter ended Dec 31, 2024 (from the annual report): revenue $26.9M, net income −$47.5M, EPS −$0.67
• Quarter ended Sep 30, 2024: revenue $0, net income −$40.2M, EPS −$0.56
• Quarter ended Jun 30, 2024: revenue $0, net income −$88.3M, EPS −$1.24
• Quarter ended Mar 31, 2024: revenue $40.6M, net income $10.1M, EPS $0.14
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$61.0M, EPS −$0.76
• Quarter ended Sep 30, 2023: revenue $0, net income −$55.5M, EPS −$0.79
• Quarter ended Jun 30, 2023: revenue $0, net income −$113M, EPS −$1.85
• Quarter ended Mar 31, 2023: revenue $0, net income −$63.2M, EPS −$1.07
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$55.0M, EPS −$0.87
• Quarter ended Sep 30, 2022: revenue n/a, net income −$54.4M, EPS −$0.96
• Quarter ended Jun 30, 2022: revenue n/a, net income −$68.4M, EPS −$1.34
• Quarter ended Mar 31, 2022: revenue n/a, net income −$59.1M, EPS −$1.31
• Quarter ended Dec 31, 2021: revenue n/a, net income −$50.1M, EPS −$1.11
• Quarter ended Sep 30, 2021: revenue n/a, net income −$4.19M, EPS −$0.09

ZNTL cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$125M, share buybacks $9.98M
• Fiscal year ended Dec 2024: operating cash flow −$171M, share buybacks $0
• Fiscal year ended Dec 2023: operating cash flow −$208M, share buybacks $0
• Fiscal year ended Dec 2022: operating cash flow −$164M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$154M, share buybacks n/a

ZNTL balance sheet

• Jun 30, 2026: cash $24.8M, total assets $215M, total liabilities $71.7M, shareholders' equity $144M
• Mar 31, 2026: cash $31.9M, total assets $253M, total liabilities $70.4M, shareholders' equity $183M
• Dec 31, 2025: cash $36.0M, total assets $289M, total liabilities $72.8M, shareholders' equity $216M
• Sep 30, 2025: cash $39.1M, total assets $327M, total liabilities $74.4M, shareholders' equity $253M
• Jun 30, 2025: cash $37.6M, total assets $352M, total liabilities $77.2M, shareholders' equity $274M
• Mar 31, 2025: cash $41.9M, total assets $384M, total liabilities $88.6M, shareholders' equity $295M
• Dec 31, 2024: cash $33.9M, total assets $430M, total liabilities $93.2M, shareholders' equity $337M
• Sep 30, 2024: cash $41.3M, total assets $451M, total liabilities $96.3M, shareholders' equity $354M

What is ZNTL's revenue?

ZENTALIS PHARMACEUTICALS INC reported $0 of revenue for the fiscal year ended December 2025.

Is ZNTL profitable?

No. ZENTALIS PHARMACEUTICALS INC lost $140M over the last four quarters.

What is ZNTL's EPS?

Diluted earnings per share over the last four quarters were −$1.96; −$0.59 in the latest quarter.

ZNTL ownership and insider trades · All stocks